DaVita Q3 revenue beat analyst estimates on increased average reimbursement rates
DVA•DaVita reported Q3 revenue of $3.58 billion and adjusted EPS of $3.82, beating analyst estimates of $3.51 billion and $3.61. It raised the lower end of its 2026 adjusted operating income guidance to $2.175 billion, while maintaining its EPS and free cash flow outlooks.
1. Q3 results
DaVita’s Q3 revenue and adjusted EPS beat analyst expectations. Revenue was $3.58 billion versus a $3.51 billion consensus estimate, and adjusted EPS was $3.82 versus $3.61. Q3 EPS was $3.40.
2. Revenue and costs
The company said increased average reimbursement rates and improvements in payor mix helped revenue. Higher medical supplies expenses drove up patient care costs per treatment. Results included $62 million in non-cash goodwill and other asset impairment charges related to its China business.
3. 2026 outlook
DaVita raised its 2026 adjusted operating income guidance to $2.175 billion-$2.25 billion from $2.15 billion-$2.25 billion. It maintained adjusted diluted EPS guidance of $14.30-$15.20 and reiterated free cash flow outlook of $1.0 billion-$1.25 billion. The company repurchased 0.6 million shares in Q3 at an average $186.21 per share.
